Your search returned 7 results.

Results
	1.	The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. [electronic resource] by Soundararajan, Sridharan Chen, Weiwei Spicer, Eleanor K Courtenay-Luck, Nigel Fernandes, Daniel J Producer: 20080425 In: Cancer research vol. 68 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. [electronic resource] by Johdi, Nor Adzimah Harman, Ruth Sanjuan, Irene Kousparou, Christina Courtenay-Luck, Nigel Deonarain, Mahendra P Producer: 20130904 In: Protein expression and purification vol. 88 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. [electronic resource] by Soundararajan, Sridharan Wang, Li Sridharan, Vijayalakshmi Chen, Weiwei Courtenay-Luck, Nigel Jones, David Spicer, Eleanor K Fernandes, Daniel J Producer: 20091123 In: Molecular pharmacology vol. 76 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. [electronic resource] by Lo, Kin-Ming Lan, Yan Lauder, Scott Zhang, Jinyang Brunkhorst, Beatrice Qin, Guozhong Verma, Rakesh Courtenay-Luck, Nigel Gillies, Stephen D Producer: 20070516 In: Cancer immunology, immunotherapy : CII vol. 56 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. [electronic resource] by Pegram, Mark D Borges, Virginia F Ibrahim, Nuhad Fuloria, Jyotsna Shapiro, Charles Perez, Susan Wang, Karen Schaedli Stark, Franziska Courtenay Luck, Nigel Producer: 20100302 In: Breast cancer research : BCR vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. [electronic resource] by Walter, Harriet S Rule, Simon A Dyer, Martin J S Karlin, Lionel Jones, Ceri Cazin, Bruno Quittet, Philippe Shah, Nimish Hutchinson, Claire V Honda, Hideyuki Duffy, Kevin Birkett, Joseph Jamieson, Virginia Courtenay-Luck, Nigel Yoshizawa, Toshio Sharpe, John Ohno, Tomoya Abe, Shinichiro Nishimura, Akihisa Cartron, Guillaume Morschhauser, Franck Fegan, Christopher Salles, Gilles Producer: 20160614 In: Blood vol. 127 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. [electronic resource] by Kwok, Hang Fai Buick, Richard J Kuehn, Diana Gormley, Julie A Doherty, Declan Jaquin, Thomas J McClurg, Angela Ward, Claire Byrne, Teresa Jaworski, Jacob Leung, Ka Lai Snoddy, Philip McAnally, Christine Burden, Roberta E Gray, Breena Lowry, Jenny Sermadiras, Isabelle Gruszka, Natalia Courtenay-Luck, Nigel Kissenpfennig, Adrien Scott, Christopher J Johnston, James A Olwill, Shane A Producer: 20130208 In: Molecular cancer vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)